A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment
Background. Recent clinical trials proven the clinically significant efficacy and tolerability of nivolumab, a programmed death 1 (PD-1) inhibitor, in previously treated patients with non-small cell lung cancer (NSCLC). Case Presentation. Here, we describe the case of a patient who experienced possi...
Saved in:
Main Authors: | Shotaro Chubachi, Hiroyuki Yasuda, Hidehiro Irie, Koichi Fukunaga, Katsuhiko Naoki, Kenzo Soejima, Tomoko Betsuyaku |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Case Reports in Oncological Medicine |
Online Access: | http://dx.doi.org/10.1155/2016/1075641 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer
by: Suyanto Suyanto, et al.
Published: (2019-01-01) -
Acute Interstitial Nephritis in a Patient with Non-Small Cell Lung Cancer under Immunotherapy with Nivolumab
by: Panagiotis I. Georgianos, et al.
Published: (2019-01-01) -
Nivolumab Effective for Gastric and Lung Cancers but Not for Multiple Myeloma in a Multiple Primary Cancer Patient
by: Tsukasa Yasuda, et al.
Published: (2021-01-01) -
Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer
by: Kavita Agrawal, et al.
Published: (2019-01-01) -
Remarkable Differences in Calcification between the Primary Tumor and Metastatic Lymph Nodes in a Patient with ALK-Positive Non-Small-Cell Lung Cancer
by: Keeya Sunata, et al.
Published: (2022-01-01)